ABSTRACT
The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic benefits and adverse effects of prolonged use of “medical marijuana” in a cohort of seriously ill patients approved through the Compassionate Investigational New Drug (IND) program of the Food and Drug Administration (FDA) for legal use of cannabis obtained from the National Institute on Drug Abuse (NIDA), under the supervision of a study physician. The aim was to examine the overall health status of eight surviving patients in the program. Four patients were able to take part, while three wished to remain anonymous, and one was too ill to participate. Unfortunately, that person, Robert Randall, succumbed to his condition during the course of the study. Thus, seven surviving patients in the United States remain in the Compassionate IND program.
